Standout Papers
Citation Impact
Citing Papers
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
2012
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
The Absence of Pericytes Does Not Increase the Sensitivity of Tumor Vasculature to Vascular Endothelial Growth Factor-A Blockade
2010
VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
2010
Targeted Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia
2006
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
2008
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
2010
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
2005
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
2004 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Heterogeneity of the Tumor Vasculature
2010
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
Pathways mediating VEGF-independent tumor angiogenesis
2009
EGFR Antagonists in Cancer Treatment
2008 Standout
Tumour–host interactions: implications for developing anti-cancer therapies
2006
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
2005 Standout
Focus on lymphangiogenesis in tumor metastasis
2005
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
2007
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
2006
Comparing antibody and small-molecule therapies for cancer
2006
Genetics, epigenetics and pharmaco‐(epi)genomics in angiogenesis
2008
Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
2009
Drug penetration in solid tumours
2006 Standout
Autocrine VEGF Signaling Is Required for Vascular Homeostasis
2007
Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma
2006
Therapeutic targeting of the tumor microenvironment
2005
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis
2007
Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
2008
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
2012
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
2005
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Imaging angiogenesis of genitourinary tumors
2010
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis
2005
Sustained delivery of a HIF-1 antagonist for ocular neovascularization
2013 StandoutNobel
Soft-Tissue Sarcomas in Adults
2005 Standout
A New Weapon for Attacking Tumor Blood Vessels
2008 StandoutNobel
CCR4 as a novel molecular target for immunotherapy of cancer
2006
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
2006
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
2007
Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage
2010
Follicular B helper T cells in antibody responses and autoimmunity
2005
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
2006
Colorectal cancer
2019 Standout
Cetuximab for the Treatment of Colorectal Cancer
2007
Global cancer statistics
2011 Standout
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
2009
Chemotherapy and the war on cancer
2005 Standout
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy
2003
Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
2009 Standout
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
2007
Immunity, Inflammation, and Cancer
2010 Standout
Effects of Intraocular Ranibizumab and Bevacizumab in Transgenic Mice Expressing Human Vascular Endothelial Growth Factor
2009
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
2006
VEGF-A: a critical regulator of blood vessel growth
2009
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
2005
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
2008
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
2013
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
2006 Nature
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Molecular basis for sunitinib efficacy and future clinical development
2007
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
2007
Microenvironmental regulation of metastasis
2008 Standout
Biomarkers of response and resistance to antiangiogenic therapy
2009
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
2008
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Pathophysiological consequences of VEGF-induced vascular permeability
2005 Nature
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
2010
Predicting benefit from anti-angiogenic agents in malignancy
2006
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model
2005
Cancer-related inflammation
2008 StandoutNature
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF
2005
Why Well-Insured Patients Should Demand Value-Based Insurance Benefits
2007
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines
2005
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
2008
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
2007
Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer
2004
Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib
2007
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma
2004
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
2008
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies
2005
VEGF-A and the Induction of Pathological Angiogenesis
2007
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
2007
Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
2006
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
The role of neuropilins in cancer
2006
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
2008
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
2004
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
2007
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
2005
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
2007
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Therapeutic Targeting of the Tumor Microenvironment
2021
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
2007
Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK
2006
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
2011
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
2004
Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
2007
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
2007
Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma
2004
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
2005
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies
2004
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
2006 Science
Vascular Endothelial Growth Factor
2009 Standout
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Angiogenesis
2006
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors
2007
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
2010
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
2007
Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)
2006
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Global cancer statistics, 2012
2015 Standout
Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
2007
Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer
2005
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Immune Therapy for Cancer
2008
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells
2005
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
2005
Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma
2006
Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
2002
Works of Beth Rogers being referenced
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout